- Home
- GBLI vs BCYC Comparison
GBLI vs BCYC Comparison
Compare GBLI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- BCYC
- Stock Information
- Founded
- GBLI 2016
- BCYC 2009
- Country
- GBLI United States
- BCYC United Kingdom
- Employees
- GBLI N/A
- BCYC N/A
- Industry
- GBLI Property-Casualty Insurers
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- GBLI Finance
- BCYC Health Care
- Exchange
- GBLI Nasdaq
- BCYC Nasdaq
- Market Cap
- GBLI 428.9M
- BCYC 492.1M
- IPO Year
- GBLI 2003
- BCYC 2019
- Fundamental
- Price
- GBLI $29.00
- BCYC $8.11
- Analyst Decision
- GBLI
- BCYC Buy
- Analyst Count
- GBLI 0
- BCYC 11
- Target Price
- GBLI N/A
- BCYC $22.91
- AVG Volume (30 Days)
- GBLI 2.7K
- BCYC 317.4K
- Earning Date
- GBLI 10-30-2025
- BCYC 10-31-2025
- Dividend Yield
- GBLI 4.84%
- BCYC N/A
- EPS Growth
- GBLI N/A
- BCYC N/A
- EPS
- GBLI 1.98
- BCYC N/A
- Revenue
- GBLI $439,280,000.00
- BCYC $19,281,000.00
- Revenue This Year
- GBLI $5.48
- BCYC N/A
- Revenue Next Year
- GBLI $7.91
- BCYC N/A
- P/E Ratio
- GBLI $14.57
- BCYC N/A
- Revenue Growth
- GBLI N/A
- BCYC N/A
- 52 Week Low
- GBLI $26.94
- BCYC $6.10
- 52 Week High
- GBLI $37.00
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- GBLI 45.64
- BCYC 50.48
- Support Level
- GBLI $28.75
- BCYC $7.87
- Resistance Level
- GBLI $29.68
- BCYC $8.95
- Average True Range (ATR)
- GBLI 0.52
- BCYC 0.53
- MACD
- GBLI -0.04
- BCYC -0.01
- Stochastic Oscillator
- GBLI 37.94
- BCYC 31.26
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.